Unmet Needs:

• Two drugs are recently approved for use on early Alzheimer’s disease (AD) patients. The efficacy is less than 30%. There are significant toxicity, brain edema, associated with the treatment.
• It has been confirmed that AD is caused by autoimmune disorders. No treatments are currently effective for treating this autoimmune disease.

STM-003: A multi-target immunotherapy in treating AD

STM-003 is a first-in-class immunotherapy to target all stages of AD with a hope to be able to „CURE“AD” and enable patients to return to normal cognitive behaviors.